Alzamend Recruits Altasciences To Conduct Early-Stage Trial Of Its Alzheimer's Candidate

by Vandana Singh, Benzinga Editor

August 17, 2021 10:59 AM | 1 min read | Make a Comment

Alzamend Neuro Inc ALZN contracted Altasciences to conduct a six-month Phase 1 comparative bioavailability study for AL001 for dementia related to Alzheimer's disease in September 2021.
AL001 is a lithium-delivering ionic cocrystal under development as an oral treatment.
The Phase 1 study will investigate the pharmacokinetics of lithium following a single dose of AL001 compared to a typical single dose of a marketed 300 mg immediate-release lithium carbonate capsule in healthy subjects.
The lithium and salicylate components of AL001 will be given within the amounts already approved for use in patients.
Related: Alzamend Neuro's Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models.
Price Action: ALZN shares are down 4.77% at $3.33 during the market session on the last check Tuesday.

Posted In: Biotech News Penny Stocks Health Care Movers Trading Ideas General alzheimer's treatment Briefs Phase 1 Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.